Flow cytometric immunophenotyping of canine adipose-derived mesenchymal stem cells (ADMSCs) and feline ADMSCs using anti-human antibodies
2018
Ko, M., Kangwon National University, Chuncheon, Republic of Korea | Lee, K.Y., Kangwon National University, Chuncheon, Republic of Korea | Kim, S.H., Seoul National University Hospital, Seoul, Republic of Korea | Kim, M., Seoul National University Hospital, Seoul, Republic of Korea | Choi, J.H., Kangwon National University, Chuncheon, Republic of Korea | Im, W., Seoul National University Hospital, Seoul, Republic of Korea | Chung, J.Y., Kangwon National University, Chuncheon, Republic of Korea
Various trials have been conducted to develop therapies for serious untreatable diseases. Among these, those using stem cells have shown great promise, and adipose-derived mesenchymal stem cells (ADMSCs) are easier to obtain than other types of stem cells. Prior to clinical trials, characterization of ADMSCs with monoclonal antibodies should be performed. However, it is difficult to use species-specific antibodies for veterinarians. This study was conducted to confirm the panel of human antibodies applicable for use in immunophenotypic characterization of canine adipose-derived stem cells and feline ADMSCs extracted from subcutaneous adipose tissue collected during ovariohysterectomy. For flow cytometric immunophenotyping, the third passages of canine ADMSC and feline ADMSC and human CD31, CD34, CD42, CD44, CD62 and CD133 antibodies were used. Of these, CD133 reacted with canine cells (3.74%) and feline cells (1.34%). CD133 is known as a marker related with more primitive stem cell phenotype than other CD series. Because this human CD133 was not a species-specific antibody, accurate percentages of immunoreactivity were not confirmed. Nevertheless, the results of this study confirmed human CD133 as a meaningful marker in canine and feline ADMSCs.
显示更多 [+] 显示较少 [-]